AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

NanoVibronix, Inc. Common Stock

$3.43 -$25.97 (-88.33%)
NASDAQ · 14 Sep 2026 19:59 UTC
Previous Close
$3.58
Day Range
$3.33$3.58
Year Range
$0.29$5.98
Market Cap
2.66M
AVG Volume
93.13K
Trailing/Forward PE
-0/-
PEG ratio
0
Dividend Yield
-
Next Earnings Date
2026-11-17
Primary Exchange
NASDAQUS
Revenue (USD)
0500K1M1.5M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
FEED Revenue (USD) by quarter
PeriodRevenue (USD)
26 Q2239K
26 Q1653K
25 Q4312K
25 Q3722K
25 Q2494K
25 Q11.02M
24 Q4444K
24 Q3376K
24 Q2817K
24 Q1921K
Net Income (USD)
-15M-10M-5M05M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
FEED Net Income (USD) by quarter
PeriodNet Income (USD)
26 Q2-4.9M
26 Q1-3.82M
25 Q4-12.85M
25 Q3600K
25 Q2-156K
25 Q1-2.5M
24 Q4-1.43M
24 Q3-998K
24 Q2-688K
24 Q1-588K
Operating Income (USD)
-6M-4M-2M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
FEED Operating Income (USD) by quarter
PeriodOperating Income (USD)
26 Q2-5.47M
26 Q1-3.71M
25 Q4-3.66M
25 Q3-2.25M
25 Q2-3.98M
25 Q1-1.85M
24 Q4-1.37M
24 Q3-970K
24 Q2-674K
24 Q1-568K
EBITDA (USD)
-8M-6M-4M-2M02M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
FEED EBITDA (USD) by quarter
PeriodEBITDA (USD)
26 Q2-5.25M
26 Q1-3.54M
25 Q4-6.51M
25 Q3855K
25 Q2-3.4M
25 Q1-2.41M
24 Q4-1.43M
24 Q3-995K
24 Q2-683K
24 Q1-568K
Cash Flows (USD)
-6M-4M-2M023 Q324 Q124 Q224 Q325 Q125 Q225 Q325 Q426 Q126 Q2
FEED Cash Flows (USD) by quarter
PeriodCash Flows (USD)
26 Q2-2.72M
26 Q1-4.33M
25 Q4-2.7M
25 Q3-2M
25 Q2-3.39M
25 Q1-1.35M
24 Q3-836K
24 Q2-555K
24 Q1-580K
23 Q3-682K
EPS (USD)
-100000-75000-50000-25000024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
FEED EPS (USD) by quarter
PeriodEPS (USD)
26 Q2-23.76
26 Q1-82532.04
25 Q4-190.44
25 Q3-10.92
25 Q2-123.6
25 Q1-477.6
24 Q4-45.09
24 Q3-39.16
24 Q2-27.18
24 Q1-25.77
Expenses (USD)
02M4M6MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
FEED Expenses (USD) by quarter
PeriodExpenses (USD)
23 Q30
26 Q25.24M
26 Q13.67M
25 Q43.31M
25 Q32.46M
25 Q23.94M
25 Q12.23M
24 Q41.65M
24 Q31.1M
24 Q21.1M
24 Q11.23M
Cash & Debt (USD)
02M4M6M8MCashLong Term DebtShort Term Debt24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
FEED Cash & Debt (USD) by quarter
PeriodCash & Debt (USD)
26 Q21.14M
26 Q12.27M
25 Q44.22M
25 Q36.95M
25 Q24.06M
25 Q1601K
24 Q4752K
24 Q31.3M
24 Q22.17M
24 Q12.7M
Debt ratios
-1-0.500.5124 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
FEED Debt ratios by quarter
PeriodDebt ratios
26 Q2-0.01
26 Q10.08
25 Q40.26
25 Q30.59
25 Q20.24
25 Q1-0.6
24 Q40.17
24 Q30.4
24 Q20.78
24 Q10.88
Margins
-150%-100%-50%0%50%100%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
FEED Margins by quarter
PeriodMargins
26 Q2-111.3%
26 Q1-8.42%
25 Q4-118.59%
25 Q326.18%
25 Q2-7.09%
25 Q136%
24 Q463.74%
24 Q335.37%
24 Q252.39%
24 Q172.1%
Return on Capital
-300%-200%-100%0%100%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
FEED Return on Capital by quarter
PeriodReturn on Capital
26 Q2-15.93%
26 Q1-11.94%
25 Q4-38.37%
25 Q31.41%
25 Q2-0.39%
25 Q1-6.99%
24 Q4-228.23%
24 Q3-53.31%
24 Q2-24.22%
24 Q1-16.78%
Shares Outstanding
0200K400K600K24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
FEED Shares Outstanding by quarter
PeriodShares Outstanding
26 Q2513.1K
26 Q1274
25 Q471.54K
25 Q371.54K
25 Q24.04K
25 Q15.22K
24 Q431.73K
24 Q325.48K
24 Q225.31K
24 Q122.82K
Book Value Per Share (USD)
05000010000015000024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
FEED Book Value Per Share (USD) by quarter
PeriodBook Value Per Share (USD)
26 Q259.94
26 Q1116843.07
25 Q4468.25
25 Q3593.6
25 Q210024.02
25 Q16836.91
24 Q419.76
24 Q373.46
24 Q2112.24
24 Q1153.55
Total Assets (USD)
020M40M60M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
FEED Total Assets (USD) by quarter
PeriodTotal Assets (USD)
26 Q238.41M
26 Q139.87M
25 Q441.12M
25 Q354.38M
25 Q251.48M
25 Q144.1M
24 Q43.63M
24 Q34.68M
24 Q25.7M
24 Q16.24M
Free Cash Flow Yield
-1500000%-1000000%-500000%0%med -1087.87%Mar 26May 26Jun 26Jul 26Aug 26Sep 26
FEED Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-667.29%
Sep 26-639.33%
Sep 26-567.94%
Aug 26-1096923%
Aug 26-965947.12%
Aug 26-864559.54%
Aug 26-943810.83%
Jul 26-1195327.7%
Jul 26-989146.72%
Jul 26-907874.14%
Jul 26-714557.09%
Jul 26-726008.33%
Jun 26-655613.89%
Jun 26-562070.96%
Jun 26-455305.73%
Jun 26-434352.06%
May 26-1218.57%
May 26-1087.87%
May 26-998.86%
May 26-923.32%
May 26-923.32%
Apr 26-819.96%
Apr 26-695.41%
Apr 26-661.9%
Apr 26-560.59%
Mar 26-452.16%
Mar 26-915.62%
Mar 26-607.04%
Mar 26-546.64%
Price to Sales
00.511.5med 0.4Nov 25Jan 26Mar 26Apr 26Jun 26Jul 26Sep 26
FEED Price to Sales by quarter
PeriodPrice to Sales
Sep 260.91
Sep 260.95
Sep 261.07
Aug 260
Aug 260
Aug 260
Aug 260
Jul 260
Jul 260
Jul 260
Jul 260
Jul 260
Jun 260
Jun 260
Jun 260
Jun 260
May 260.3
May 260.34
May 260.37
May 260.4
May 260.4
Apr 260.45
Apr 260.53
Apr 260.56
Apr 260.66
Mar 260.82
Mar 260.4
Mar 260.61
Mar 260.68
Feb 260.67
Feb 260.88
Feb 260.9
Feb 260.93
Jan 261.03
Jan 260.35
Jan 260.42
Jan 260.74
Jan 260.78
Dec 250.82
Dec 250.96
Dec 251.31
Dec 251.33
Nov 250.09
Nov 250.08
Nov 250.09
Price to Book
00.030.050.080.1med 0.03Nov 25Jan 26Mar 26Apr 26Jun 26Jul 26Sep 26
FEED Price to Book by quarter
PeriodPrice to Book
Sep 260.06
Sep 260.06
Sep 260.07
Aug 260
Aug 260
Aug 260
Aug 260
Jul 260
Jul 260
Jul 260
Jul 260
Jul 260
Jun 260
Jun 260
Jun 260
Jun 260
May 260.02
May 260.03
May 260.03
May 260.03
May 260.03
Apr 260.03
Apr 260.04
Apr 260.04
Apr 260.05
Mar 260.06
Mar 260.03
Mar 260.05
Mar 260.05
Feb 260.04
Feb 260.06
Feb 260.06
Feb 260.06
Jan 260.07
Jan 260.02
Jan 260.03
Jan 260.05
Jan 260.05
Dec 250.05
Dec 250.06
Dec 250.08
Dec 250.08
Nov 250
Nov 250
Nov 250.01
NanoVibronix, Inc. Common Stock
FEED
Stockpicker

Video analysis: FEED

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: FEED

ENvue Medical Resumes U.S. Commercial Shipments of NanoVibronix PainShield® and Begins Fulfilling Open Distributor Orders

globenewswire.com · 9 Sep 2026

ENvue Medical Resumes U.S. Commercial Shipments of NanoVibronix PainShield® and Begins Fulfilling Open Distributor Orders

TYLER, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- ENvue Medical , Inc. (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement and therapeutic technologies, today announced that it has resumed commercial shipments of PainShield®, manufactured in the United States, and has begun fulfilling open orders from Ultra Pain Products, Inc. (“UPPI”), the Company's exclusive U.S. distribution partner for the product.

ENvue Medical Selected to Exhibit ENvue™ Navigation Platform at Vizient Innovative Technology Exchange

globenewswire.com · 2 Sep 2026

ENvue Medical Selected to Exhibit ENvue™ Navigation Platform at Vizient Innovative Technology Exchange

TYLER, Texas, Sept. 02, 2026 (GLOBE NEWSWIRE) -- ENvue Medical (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced it has been selected to exhibit its ENvue™ Navigation Platform, a minimally invasive electromagnetic navigation system guiding feeding tube placement, at the Vizient® Innovative Technology Exchange.

ENvue Medical Announces Exclusive UroShield® Distribution Agreement with Minimum Purchase Commitments of Approximately $2.6 Million

globenewswire.com · 18 Aug 2026

ENvue Medical Announces Exclusive UroShield® Distribution Agreement with Minimum Purchase Commitments of Approximately $2.6 Million

Multi-year agreement with Peak Medical expands UroShield commercialization across the United Kingdom and Republic of Ireland Multi-year agreement with Peak Medical expands UroShield commercialization across the United Kingdom and Republic of Ireland

ENvue Medical Secures Equity Financing Facility of Up to $50 Million to Support Commercial Growth, Technology Expansion and Strategic Acquisitions

globenewswire.com · 12 Aug 2026

ENvue Medical Secures Equity Financing Facility of Up to $50 Million to Support Commercial Growth, Technology Expansion and Strategic Acquisitions

TYLER, Texas, Aug. 12, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) ("ENvue" or the "Company"), a commercial-stage medical technology company, today announced that it has entered into a securities purchase agreement (“ELOC”) with an institutional investor providing the Company with an equity facility for up to $50 million in capital (the “Facility”), subject to the terms and conditions of the agreement, including the receipt of stockholder approval.

ENvue Medical Moves NanoVibronix Manufacturing to the United States, Consolidates R&D in Tel Aviv, Israel, Increasing Operational Efficiencies and Cost Reduction Opportunities

globenewswire.com · 4 Aug 2026

ENvue Medical Moves NanoVibronix Manufacturing to the United States, Consolidates R&D in Tel Aviv, Israel, Increasing Operational Efficiencies and Cost Reduction Opportunities

TYLER, Texas, Aug. 04, 2026 (GLOBE NEWSWIRE) -- ENvue Medical , Inc. (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company, today announced it has completed the transition of its NanoVibronix manufacturing operations from Israel to the United States, and consolidated its research and development operations in Tel Aviv, Israel, supporting the Company's broader initiative to reduce operating expenses and improve its cost structure. “Completing the transition of our NanoVibronix product line manufacturing to the United States marks the achievement of a major strategic operational initiative for the Company,” said Doron Besser, MD, CEO of ENvue Medical.

ENvue Medical Deploys Additional Navigation Platform with Existing Customer, A Leading North Texas Medical Center

globenewswire.com · 23 Jul 2026

ENvue Medical Deploys Additional Navigation Platform with Existing Customer, A Leading North Texas Medical Center

Additional Platform Deployment at Major Academic Medical Center Reflects Increasing Commercial Demand for Bedside Feeding Tube Navigation Additional Platform Deployment at Major Academic Medical Center Reflects Increasing Commercial Demand for Bedside Feeding Tube Navigation

ENvue Medical Appoints Chairman of the Board and New Directors, Bringing Clinical, AI Governance and Capital Markets Expertise to Navigation Platform

globenewswire.com · 15 Jul 2026

ENvue Medical Appoints Chairman of the Board and New Directors, Bringing Clinical, AI Governance and Capital Markets Expertise to Navigation Platform

Zeev Rotstein, M.D. Named Chairman Following Four Decades in Health System Leadership, Including 12 Years as Director General of Sheba Medical Center Zvi Joseph and Lior Buchman Join Board, Bringing Amdocs AI Governance Leadership and $320 Million in Executed Financings and M&A, Respectively TYLER, Texas, July 15, 2026 (GLOBE NEWSWIRE) -- ENvue Medical (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced that Zeev Rotstein, M.D.

Envue Medical Expands AI Navigation Platform With Robotic Prototype

benzinga.com · 9 Jul 2026

Envue Medical Expands AI Navigation Platform With Robotic Prototype

ENvue Medical, Inc. (NASDAQ:FEED) announced Thursday the development and demonstration of the prototype of ENvue Drive.

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.